Comparison
Hexarelin vs. Retatrutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
140703-51-1
2381089-83-2
Molecular weight
887.05 g/mol
4731.6 g/mol
Half-life
0.9 h
144 h
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Y-Aib-EGTFTSDYSIYLDKQAAQDFVQWLLDTGPSSGAPPPSMechanism of action
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Retatrutide
Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
3
4
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2